Navigation Links
Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea

Newport, R.I., July 25, 2012 - Migraine can be a disabling neurological disorder, often aggravated by accompanying nausea. Stimulation of the acupoint PC6 Neiguan, an approach to controlling nausea adopted by traditional Chinese medicine, has never been documented by published clinical studies in medical literature for the control of migraine-related nausea, until now. Published in the May 2012 Neurological Sciences (journal of the Italian Neurological Society)*, "Acupressure in the control of migraine-associated nausea" is a clinical trial demonstrating that continuous stimulation of the acupoint PC6 Neiguan on the inner wrist, as provided by Sea-Band wristbands, showed statistically significant improvement in migraine-related nausea versus not using the wristbands.

Previous studies have demonstrated the efficacy of Sea-Band and its continual stimulation of the acupressure point PC6 for nausea relief due to motion sickness, postoperative nausea and chemotherapy-induced nausea. However, this May 2012 study is the first published research aimed at verifying that pressure applied to the acupoint PC6 with Sea-Band is effective at relieving nausea during migraine.

Migraine affects more than 29.5 million Americans, according to the National Headache Foundation, and is considered by the World Health Organization as the 19th leading cause of all years lived with disability for both males and females. Eight out of every 10 people in the U.S. who are diagnosed with migraine report experiencing nausea.

"This new research supports what millions of Sea-Band users already know; that the acupressure wristbands provide fast, consistent, drug-free relief for nausea associated with migraine headaches," commented Leonard Nihan, president, Sea-Band U.S. "We're pleased to have this published study to reinforce Sea-Band's efficacy to the scientific and medical communities."

The Italian study included 40 female patients suffering from migraine without aura, if nausea was always present as an accompanying symptomatology of their migraine. The patients were treated randomly for a total of six migraine attacks: three with the application of Sea-Band wristbands, which applies continual pressure to the PC6 acupoint (phase SB), and three without it (phase C).

The intensities of nausea at the onset at 30, 60, 120 and 240 minutes were evaluated on a scale from zero to 10. The values were always significantly lower in phase SB than in phase C. Also the number of patients who reported at least a 50 percent reduction in the nausea score was significantly higher in phase SB than in phase C at 30, 60 and 120 minutes. The average nausea scores dropped in the SB phase from 6.36 0.35 in T0, to 4.60 0.39 in T1, to 3.11 0.40 in T2, to 1.88 0.31 in T3 and to 0.92 0.22 in T4. At each time step taken into consideration after the application of the Sea-Band wristbands, there was a statistically significant improvement over the non-treated phases. Moreover, there were a high percentage of responders to the treatment: i.e. 46.8 percent at 60 minutes; 71.8 percent at 120 minutes; 84.3 percent at 240 minutes with a consistent response over time.

Contact: Stephanie LaDue
Robin Leedy & Associates, Inc.

Related biology news :

1. New 3-D stem cell culture method published in JoVE
2. SEBM Best Paper Awards for articles published in 2011
3. Research on carbon-consuming life-forms in Antarctica published in JoVE
4. New study published on fertility awareness among American university students
5. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
6. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
7. New clinical trial explores novel noninvasive colon cancer screening test
8. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
9. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
10. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
11. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
Post Your Comments:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: